Company news
Solid Biosciences Inc. news in 2024
Solid Biosciences Inc.'s news releases, calls and decks from 2024, newest first.
Solid Biosciences Announces Collaboration with Mayo Clinic to Accelerate Gene Therapy Innovation and Advance Development of Cardiac Gene Therapies
December 3, 2024
Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates
November 5, 2024
Solid Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Updates
August 12, 2024
Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 4, 2024
Solid Biosciences Joins the Russell 3000® Index
June 30, 2024
Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results
May 14, 2024
Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
March 31, 2024
Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results
March 12, 2024
Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHD
March 6, 2024
Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
January 15, 2024
Solid Biosciences Announces $109 Million Private Placement
January 7, 2024
Decks in 2024
- 42nd Annual J.P. Morgan Healthcare Conference 2024
Conference · 30 slides · Jan 8, 2024